Biohaven (BHVN) Depreciation & Amortization (CF) (2021 - 2026)
Biohaven (BHVN) reported Depreciation & Amortization (CF) of $2.4 million for Q1 2026, up 5.34% on a YoY basis from $2.2 million in Q1 2025, and down 8.05% sequentially from $2.6 million in Q4 2025.
Biohaven (BHVN) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Biohaven (BHVN) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $2.4 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 5.34% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $10.0 million (up 16.03% YoY), and the FY2025 full-year result was $9.9 million, up 26.31% from the prior year.
- Depreciation & Amortization (CF) eased to $2.4 million in Q1 2026, from $2.6 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.1 million in Q3 2025 to a low of $250000.0 in Q1 2022.
- A 5-year average of $1.7 million and a median of $1.9 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) plunged 49.78% in 2022 and jumped 559.6% in 2023, its largest moves.
- Tracing BHVN's Depreciation & Amortization (CF) over 5 years: stood at $344000.0 in 2022, then jumped by 450.58% to $1.9 million in 2023, then increased by 29.94% to $2.5 million in 2024, then rose by 4.55% to $2.6 million in 2025, then retreated by 8.05% to $2.4 million in 2026.
- Business Quant data shows BHVN's Depreciation & Amortization (CF) at $2.4 million in Q1 2026, $2.6 million in Q4 2025, and $3.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Biohaven | 2.13 Bn | 1.78 Bn | - | 2.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.37 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Dec 31, 2023 | 1.89 Mn |